trial

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

NCTId NCT00149292
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 195 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2006-07-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
195 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2005-08-23
Primary completion
2006-07-17
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PomaglumetadOlanzapine

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

2 total
Moscow, RussiaVillage Nikolskoe, Russia

Linked catalysts

1
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo — primary completion2006-07-17

Facts & assertions

4 sourced
Enrollment
195
Phase
PHASE2
Primary Completion Date
2006-07-17
Status
COMPLETED
relationships
The graph out of here
drug
Pomaglumetad
drug
Olanzapine
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person